Carbidopa-d3 (monohydrate)

• UNSPSC Description:

  Carbidopa-d3 (monohydrate) is the deuterium labeled Carbidopa monohydrate. Carbidopa ((S)-(-)-Carbidopa) monohydrate, a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa monohydrate is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa monohydrate inhibits pancreatic cancer cell and tumor growth[1][2].

• Target Antigen:

  Aryl Hydrocarbon Receptor

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Immunology/Inflammation

• Field of Research:

  Cancer; Neurological Disease

• Purity:

  98.0

• Solubility:

  10 mM in DMSO

• Smiles:

  OC(C([2H])=C1C[C@@](NN)(C)C(O)=O)=C(C([2H])=C1[2H])O.O

• Molecular Weight:

  247.26

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Gilbert JA, et al. The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res. 2000;6(11):4365-4372.|[3]Safe S. Carbidopa: a selective Ah receptor modulator (SAhRM). Biochem J. 2017;474(22):3763-3765. Published 2017 Nov 6.|[4]Fermaglich J. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa. Med Ann Dist Columbia. 1974;43(12):587-591.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1276197-58-0